Barclays Maintains Overweight on Lumexa Imaging Hldgs, Raises Price Target to $13
Barclays analyst Andrew Mok maintains Lumexa Imaging Hldgs (NASDAQ:LMRI) with a Overweight and raises the price target from $9 to $13.
Stocks · News reference
Lumexa Imaging Holdings Q2 Adj. EPS $0.20 Beats $0.16 Estimate, Sales $264.200M Beat $263.113M Estimate
Lumexa Imaging Holdings (NASDAQ:LMRI) reported quarterly earnings of $0.20 per share which beat the analyst consensus estimate of $0.16 by 25 percent. The company reported quarterly sales of $264.200 million which beat
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Lumexa Imaging Holdings Affirms FY2026 Adj EPS Guidance of $0.71-$0.77 vs $0.62 Est; Raises FY2026 Sales Guidance from $1.045B-$1.090B to $1.045B-$1.097B vs $1.067B Est
Lumexa Imaging Holdings (NASDAQ:LMRI) affirms FY2026 Adj EPS guidance from $0.71-$0.77 to $0.71-$0.77 vs $0.62 analyst estimate. Raises FY2026 sales outlook from $1.045 billion-$1.090 billion to $1.045 billion-$1.097
8-K filing — Lumexa Imaging Holdings, Inc. (LMRI)
Filed: 2026-06-30 AccNo: 0001193125-26-290788 Size: 260 KB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 9.01: Financial Statements and Exhibits